

From *Cardiac Surgery Today* Vol. 1 No.2 2003:43-51

“Patient-Prosthesis Mismatch and the Predictive Use of Indexed Effective Orifice Area: Is it Relevant?”

Pibarot P, Dumesnil J - A Review Article

- An EOA indexed to body surface area is a statistically proven predictor of post-operative gradients and patient-prosthesis mismatch (PPM)¹ (See Figure 1)

“Studies based on indexed EOA demonstrate a 20-70% prevalence of PPM in patients undergoing aortic valve replacement surgery.”^{1,2}

- Numerous studies using indexed EOA (EOA-I) continue to demonstrate the harmful impact of patient-prosthesis mismatch, as shown in Table 1.

Due to a weak correlation between indexed geometric orifice area (GOA-I) and pressure gradients, studies using GOA-I show minimal or no impact on PPM.^{1,8,9,10} (See Figure 2)




Figure 1. Indexed EOA demonstrates a **strong correlation** to post-op gradients. An EOA-I $\leq 0.85 \text{ cm}^2/\text{m}^2$ predicts high post-op gradients and PPM.*




Figure 2. Indexed GOA shows a **weak correlation** to post-op gradients and does not predict PPM.*

Table 1 – Summary of Clinical Findings on PPM with Aortic Valve Replacement Surgery¹

Parameter	Index	Clinical Impact of PPM
LV mass and function • LV mass regression • LV systolic function (cardiac index) • Improvement of NYHA classification • Freedom from congestive heart failure • Freedom from late cardiac events	EOA-I	Decreased 4.5% with PPM compared to 23% without PPM ³ , p=0.0001, n=1,103
	EOA-I	Decreased at 5 years from baseline $\Delta -0.54$ (l/min/n) with PPM compared to $\Delta -0.017$ without PPM ⁴ , p=0.04, n=392
	EOA-I	Improved functional class by 1.5 with PPM compared to 1.9 without PPM ⁴ , p=0.009, n=392
	EOA-I	84% with PPM versus 89% without PPM ⁴ , p=0.05, n=392
	EOA-I	Only 56% with severe PPM compared to 80% with moderate PPM and 94% without PPM ⁵ , p=0.03, n=229
Early mortality	EOA-I EOA-I	7.9% with PPM compared to 4.6% without PPM ⁶ , p=0.03, n=2,154 26% with severe PPM compared to 3% without PPM ² , p<0.0001, n=1,266
Freedom from late mortality	EOA-I	Only 75.5% with PPM compared to 84.2% without PPM ⁶ , p=0.0004, n=2,154
High-risk patients • Mortality (LV ejection fraction <35%) • Mortality (LV ejection fraction <40%)	N/A	47% with small prosthesis compared to 15% with larger prosthesis ⁷ , p=0.03, n=52
	EOA-I	67% with severe PPM compared to 16% with moderate PPM and 7% without PPM ² , p<0.001, n=1,266
Risk of congestive heart failure	EOA-I	60% increased risk of CHF with severe to moderate PPM ¹² , p=0.044, n=1,226

PPM can largely be avoided using a preventive strategy. Select a prosthesis with an EOA-I $>0.85 \text{ cm}^2/\text{m}^2$. The SJM Regent[®] valve delivers the largest EOAs of any prosthetic heart valve suggesting that PPM should be unusual with this valve.^{2,11}

For PPM reference tools including an EOA-I Pocket Guide and Operating Room Calculator, contact your St. Jude Medical representative or Customer Service at **1-800-544-1664**.

* Graphs used with permission from Philippe Pibarot, DVM, Ph.D., FACC

References:

1. Pibarot P, Dumesnil JG. Patient-prosthesis mismatch and the predictive use of indexed effective orifice area: is it relevant? *Cardiac Surg Today*. 2003; 1(2): 43-51.
2. Blais C, Dumesnil JG, Baillet R, Simard S, et al. Impact of valve prosthesis-patient mismatch on short-term mortality after aortic valve replacement. *Circulation*. 2003 Aug 26; 108(8): 983-8. Epub 2003 Aug 11.
3. Del Rizzo DF, Abdoh A, Cartier P, Doty D, et al. Factors affecting left ventricular mass regression after aortic valve replacement with stentless valves. *Semin Thorac Cardiovasc Surg*. 1999 Oct; 11(4 Suppl 1): 114-20.
4. Pibarot P, Dumesnil JG, Lemieux M, Cartier P, et al. Impact of prosthesis-patient mismatch on hemodynamic and symptomatic status, morbidity and mortality after aortic valve replacement with a bioprosthetic heart valve. *J Heart Valve Dis*. 1998 Mar; 7(2): 211-8.
5. Milano AD, De Carlo M, Mecozzi G, D'Alfonso A, et al. Clinical outcome in patients with 19-mm and 21-mm St. Jude aortic prostheses: comparison at long-term follow-up. *Ann Thorac Surg*. 2002 Jan; 73(1): 37-43.
6. Rao V, Jamieson WR, Ivanov J, Armstrong S, et al. Prosthesis-patient mismatch affects survival after aortic valve replacement. *Circulation*. 2000 Nov 7; 102(19 Suppl 3): III5-9.
7. Connolly HM, Oh JK, Schaff HV, Roger VL, et al. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: result of aortic valve replacement in 52 patients. *Circulation*. 2000 Apr 25; 101(16): 1940-6.
8. Medalion B, Blackstone EH, Lytle BW, White J, Arnold JH, et al. Aortic valve replacement: is valve size important? *J Thorac Cardiovasc Surg*. 2000 May; 119(5): 963-74.
9. Fernandez J, Chen C, Laub GW, Anderson WA, et al. Predictive value of prosthetic valve area index for early and late clinical results after valve replacement with the St. Jude Medical valve prosthesis. *Circulation*. 1996 Nov 1; 94(9 Suppl): II109-12.
10. Blackstone EH, Cosgrove DM, Jamieson WR, Birkmeyer NJ, et al. Prosthesis size and long-term survival after aortic valve replacement. *J Thorac Cardiovasc Surg*. 2003 Sep; 126(3): 783-96.
11. Bach DS, Sakwa MP, Goldbach M, et al. Hemodynamics and early clinical performance of the St. Jude Medical Regent mechanical aortic valve. *Ann Thorac Surg*. 2002 Dec; 74(6): 2003-9; discussion 2009.
12. Ruel M, Rubens FD, Masters RG, et al. Late incidence and predictors of persistent or recurrent heart failure in patients with aortic prosthetic valves. *J Thorac Cardiovasc Surg*. 2004 Jan; 127(1): 149-59.

VISIT OUR WEB SITE AT www.sjm.com

St. Jude Medical prosthetic heart valves are indicated for use as replacement valves in patients with a diseased, damaged, or malfunctioning native or prosthetic valve. Possible side effects for all valvular implants include, but are not limited to: regurgitation, thromboembolic phenomena, resistance to flow, infection, hemolysis, dysrhythmias, and prosthetic dehiscence or failure. Anticoagulation is recommended for patients with mechanical valve implants. Please see the physician's manual for a full description of indications, contraindications, side effects, precautions, warnings and instructions for use.

Corporate Headquarters St. Jude Medical, Inc., One Lillehei Plaza, St. Paul, Minnesota 55117 USA **24 hour Technical/Professional Consultation** (800) 328-9634 (USA) (651) 483-2000 Fax: (651) 482-8318 **Customer Service** (800) 544-1664 (USA) (651) 490-4410 Fax: (651) 481-7702 **European Headquarters** St. Jude Medical Europe, Inc., The Corporate Village, Avenue Da Vinci laan, 11-Box F1, B-1935, Zaventem, Belgium **Customer Service** Tel: 32-2-774-68-11 Fax: 32-2-772-83-84 **Asian Headquarters** St. Jude Medical Hong Kong Limited, Room 2705-2708, China Merchants Tower, Shun Tak Centre, 168-200 Connaught Road, Central, Hong Kong Tel: (852) 2996-7688 Fax: (852) 2956-0622

The Global Leader in Heart Valve Devices is a trademark of St. Jude Medical, Inc. St. Jude Medical Cardiac Surgery Division. ©2004 St. Jude Medical, Inc. All rights reserved. Printed in the USA. ITEM 1677/0703/20M/EN/B&F

The Global Leader in Heart Valve Devices.™

 **ST. JUDE MEDICAL**